1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Market Insight - Hepatitis C: in search of a breakthrough

 
• By Gautam Thor

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Since HCV was identified as being the causative agent of Hepatitis C (non-A, non-B hepatitis), treatment has progressed rapidly, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapeutic Category

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.